Latest Insider Transactions at Translate Bio, Inc. (TBIO)
This section provides a real-time view of insider transactions for Translate Bio, Inc. (TBIO). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Translate Bio, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Translate Bio, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 14
2021
|
Jean Francois Formela Director |
SELL
Open market or private sale
|
Indirect |
2,055,063
-100.0%
|
$78,092,394
$38.0 P/Share
|
|
Sep 14
2021
|
Owen Hughes Director |
SELL
Open market or private sale
|
Direct |
29,860
-100.0%
|
$1,134,680
$38.0 P/Share
|
|
Sep 14
2021
|
Paul D. Burgess Chief Operating Officer, CLO |
SELL
Open market or private sale
|
Direct |
71,833
-100.0%
|
$2,729,654
$38.0 P/Share
|
|
Sep 14
2021
|
Ronald C Renaud Jr Chief Executive Officer |
SELL
Open market or private sale
|
Indirect |
450,822
-100.0%
|
$17,131,236
$38.0 P/Share
|
|
Sep 14
2021
|
Ronald C Renaud Jr Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
503,231
-100.0%
|
$19,122,778
$38.0 P/Share
|
|
Sep 14
2021
|
Sanofi > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
71,983,597
+34.8%
|
$2,735,376,686
$38.0 P/Share
|
|
Apr 07
2021
|
Ronald C Renaud Jr Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
9,026
+1.76%
|
$63,182
$7.39 P/Share
|
|
Jan 14
2021
|
Ronald C Renaud Jr Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,639
+0.56%
|
$39,473
$7.87 P/Share
|
|
Dec 22
2020
|
Jean Francois Formela Director |
SELL
Open market or private sale
|
Indirect |
82,565
-34.46%
|
$2,064,125
$25.46 P/Share
|
|
Dec 21
2020
|
Jean Francois Formela Director |
SELL
Open market or private sale
|
Indirect |
56,536
-30.89%
|
$1,413,400
$25.5 P/Share
|
|
Nov 16
2020
|
Ronald C Renaud Jr Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
53,007
+4.89%
|
$371,049
$7.87 P/Share
|
|
Jun 26
2020
|
Baupost Group LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
500,000
+2.7%
|
$11,000,000
$22.0 P/Share
|
|
Jul 02
2018
|
Glaxosmithkline PLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
269,230
+6.79%
|
$3,499,990
$13.0 P/Share
|
|
Jul 02
2018
|
Glaxosmithkline PLC > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
3,428,682
+30.71%
|
-
|